Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Schizophrenia Patients Must Be Treated with Fewer Drugs, at Lower Doses: Seminar
July 30, 2007
-
ARCHIVE R&D NEWS IN BRIEF(2)
July 30, 2007
-
ARCHIVE Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
-
ARCHIVE NEW PRODUCTS
July 30, 2007
-
ARCHIVE Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
-
ARCHIVE Prices Should Not Be Cut during Patent Life If Yakkasa Is Smaller than “Dispensing Margins”: EFPIA
July 30, 2007
-
ARCHIVE Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi
July 30, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Kyowa Hakko Committed to Successively Developing New Drugs: President Dr Matsuda
July 30, 2007
-
ARCHIVE 3rd Seminar on MR Mammography Fields Hottest Topics on Breast Cancer MRI
July 30, 2007
-
ARCHIVE Pfizer Expanding Supply of Information on JZOLOFT to PCP
July 30, 2007
-
ARCHIVE Pacemakers Are Much Higher-Priced in Japan Than in South Korea, Thailand: Survey
July 30, 2007
-
ARCHIVE Janssen to Differentiate Risperdal from Generics
July 30, 2007
-
ARCHIVE Major Medical Systems Used for 10.3 Years
July 30, 2007
-
ARCHIVE Alfresa to Reduce SGA Expanses Ratio to Below 6% by FY2009
July 30, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Benefits for OTC-Like Ethical Drugs to Be Reviewed in 4 to 5 Years
July 30, 2007
-
ARCHIVE 11 Generic Products (6 APIs) to Be Listed in November
July 30, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…